for use as screening tests. Like the situation with C-reactive protein as a CVD risk biomarker, they can perhaps be best used in patients with intermediate risk and/or when there appears to be discordance between a patient’s clinical presentation and conventional lipid biomarker measurements. In the case of NMR and mass spectrometry-based testing, the ability to add new markers for CVD and other diseases without much additional cost may make these approaches more attractive in the future.

Anna Wolska, PhD, and Alan T. Remaley, MD, PhD, have received research support from LipoScience Inc., Remaley, MD, PhD, have received research support from LipoScience Inc., which was acquired by LabCorp Inc.

Anna Wolska, PhD, and Alan T. Remaley, MD, PhD, have received research support from LipoScience Inc., which was acquired by LabCorp Inc. in 2014.

Anna Wolska, PhD, is a postdoctoral fellow in the Lipoprotein Metabolism Section of the Pulmonary and Vascular Medicine Branch at the National Institutes of Health. +EMAIL: anna.wolska@nih.gov

Alan T. Remaley, MD, PhD, is the senior investigator in the Lipoprotein Metabolism Section of the Pulmonary and Vascular Medicine Branch at the National Institutes of Health. +EMAIL: aremaley1@nhlbi.nih.gov

### REFERENCES